Literature DB >> 24780186

MicroRNA-152 targets ADAM17 to suppress NSCLC progression.

Yunshu Su1, Yuchang Wang1, Hongmin Zhou1, Lei Lei1, Lijun Xu2.   

Abstract

MicroRNAs (miRNAs) are a class of small non-coding RNAs that have been suggested to play an essential role in tumorigenesis. In this study, we show that miR-152 is significantly downregulated in non-small cell lung cancer (NSCLC) tissues and cell lines. Restoration of miR-152 significantly reduces proliferation, colony formation, migration and invasion of NSCLC cells. In addition, ADAM metallopeptidase domain 17 (ADAM17) is identified as a target of miR-152 in NSCLC cells, and miR-152-induced suppression of cell proliferation, colony formation, migration and invasion is partially mediated by silencing of ADAM17 expression. Furthermore, ADAM17 inversely correlates with miR-152 in NSCLC tissues. Collectively, our findings indicate that miR-152 acts as tumor suppressor in NSCLC partially via targeting ADAM17.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADAM metallopeptidase domain 17; Invasion; Migration; Non-small cell lung cancer; Proliferation; miR-152

Mesh:

Substances:

Year:  2014        PMID: 24780186     DOI: 10.1016/j.febslet.2014.04.022

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

Review 1.  Cell-free microRNAs in blood and other body fluids, as cancer biomarkers.

Authors:  Blanca Ortiz-Quintero
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

Review 2.  Gene expression profiling in the human alcoholic brain.

Authors:  Anna S Warden; R Dayne Mayfield
Journal:  Neuropharmacology       Date:  2017-03-15       Impact factor: 5.250

Review 3.  Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.

Authors:  Alti Dayakar; Kumar D Shanmukha; Suresh K Kalangi
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.742

4.  Expression and clinical significance of microRNA-152 in supragalottic laryngeal carcinoma.

Authors:  Yan Song; Yuan Tian; Wei-Liang Bai; Xiu-Lan Ma
Journal:  Tumour Biol       Date:  2014-08-06

5.  MiR-338-3p inhibits the proliferation and migration of gastric cancer cells by targeting ADAM17.

Authors:  Jiang-Tao Chen; Kun-Hou Yao; Long Hua; Li-Ping Zhang; Chen-Yu Wang; Jun-Jie Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  MicroRNA-506 inhibits esophageal cancer cell proliferation via targeting CREB1.

Authors:  Wen-Jian Yao; Yong-Lian Wang; Jian-Guo Lu; Ling Guo; Bo Qi; Zhi-Jun Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer.

Authors:  Hengli Dou; Yan Wang; Gang Su; Song Zhao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

8.  Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.

Authors:  Yuduo Guo; Xin He; Mingshan Zhang; Yanming Qu; Chunyu Gu; Ming Ren; Haoran Wang; Weihai Ning; Junfa Li; Chunjiang Yu; Hongwei Zhang
Journal:  J Neurooncol       Date:  2020-03-13       Impact factor: 4.130

9.  miR-152 as a tumor suppressor microRNA: Target recognition and regulation in cancer.

Authors:  Xuexiang Liu; Jinwan Li; Fengxian Qin; Shengming Dai
Journal:  Oncol Lett       Date:  2016-04-28       Impact factor: 2.967

10.  Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer.

Authors:  Urszula Dougherty; Reba Mustafi; Hongyan Zhu; Xiaorong Zhu; Dilip Deb; Stephen C Meredith; Fatma Ayaloglu-Butun; Michelle Fletcher; Arantxa Sanchez; Joel Pekow; Zifeng Deng; Nader Amini; Vani J Konda; Vijaya L Rao; Atsushi Sakuraba; Akushika Kwesi; Sonia S Kupfer; Alessandro Fichera; Loren Joseph; John Hart; Fang He; Tong-Chuan He; Diana West-Szymanski; Yan Chun Li; Marc Bissonnette
Journal:  Epigenetics       Date:  2020-12-28       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.